FDA Approves BioCardia’s CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

DENVER, Colo., Nov 14, 2023 (www.247marketnews.com)- BioCardia Inc (NASDAQ:BCDA) stated, this morning, that the Food and Drug Administration (FDA) approved its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure and its proposed CardiAMP Heart Failure II study protocol.

BioCardia is trading at $0.7628, up $0.3638 (+91.18%), on 4.65M premarket shares.

Its 52-week range is $0.36 to $2.9199. It broe through a 2.5 month channel and is set to challenge several resistance points, if its strong trading volume continues.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.